Compound Glycyrrhizin Injection segmentation by application reveals four principal therapeutic clusters that collectively drive market revenue. The hepatitis treatment segment, accounting for roughly 45 % of sales, dominates because glycyrrhizin’s antiviral and hepatoprotective properties align with high prevalence of chronic hepatitis B and C in Asia-Pacific. The liver‑cirrhosis cluster contributes about 30 % of the market; clinicians favor the injection to mitigate fibrosis progression and improve biochemical markers, supporting a stable demand despite emerging oral agents. Immunomodulatory therapy, representing 15 % of the market, reflects off‑label use in autoimmune hepatitis and systemic inflammatory conditions, where the compound’s cytokine‑modulating effects generate niche but growing prescriptions. The residual 10 % falls under “other applications,” encompassing experimental oncology trials and acute liver injury protocols, which add incremental volume but remain volatile. Together, these application categories define the market’s shape, with each segment’s share directly proportional to disease incidence, reimbursement policies, and clinical guideline endorsement. Consequently, strategic portfolio decisions prioritize hepatitis and cirrhosis indications to capture the majority of revenue while monitoring emerging opportunities in immunomodulation and exploratory uses.
